Pramlintide
pramlintide acetate, AC137, tri-pro-amylin, 25,28,29-tripro-human amylin
Pramlintide is a synthetic analogue of human amylin, the second hormone secreted by pancreatic beta cells alongside insulin. It is licensed in the United States as a mealtime adjunct to insulin in type 1 and type 2 diabetes. It is the only amylin-receptor agonist to have reached the market, and it carries a boxed warning for severe insulin-induced hypoglycaemia.
Mechanism
Human amylin, also called islet amyloid polypeptide, is co-secreted with insulin from beta cells in roughly a 1:100 molar ratio and is therefore deficient in anyone who has lost beta-cell function. Native human amylin is strongly amyloidogenic and forms the islet fibrils characteristic of type 2 diabetes, which makes it useless as a medicine. Pramlintide solves this by substituting proline at positions 25, 28 and 29, copying the corresponding residues of rat amylin, which does not aggregate. The result is a soluble, injectable peptide with intact receptor activity.
Pramlintide acts at amylin receptors, which are not standalone proteins but heterodimers formed when the calcitonin receptor associates with one of three receptor activity-modifying proteins, producing the AMY1, AMY2 and AMY3 subtypes. The principal site of action is the area postrema, a circumventricular structure outside the blood-brain barrier. Three physiological effects follow: gastric emptying is slowed, so nutrient delivery to the small intestine is spread out; postprandial glucagon secretion, which is inappropriately elevated in diabetes, is suppressed; and satiety is enhanced. Critically, pramlintide is not an insulin secretagogue and has no direct effect on the beta cell. It works purely by reshaping the postprandial glucose curve, which is why it is used with, and never instead of, mealtime insulin.
What the research shows
Three 52-week randomised, double-blind, placebo-controlled trials established the licensed effect. In type 1 diabetes, Whitehouse and colleagues randomised 480 patients, of whom 342 completed 52 weeks, and reported a mean HbA1c reduction of 0.67 percentage points with pramlintide, a placebo-adjusted difference of roughly 0.3 to 0.4 points, with favourable weight change but a clear early excess of severe hypoglycaemia. Ratner and colleagues, in 651 patients with type 1 diabetes, found HbA1c reductions of roughly 0.3 percentage points sustained at 52 weeks alongside a weight difference of about 1.8 kg in favour of pramlintide, with three times as many patients reaching target. In insulin-treated type 2 diabetes, Hollander and colleagues studied 656 patients and reported an HbA1c reduction of 0.62 percentage points at 120 micrograms twice daily versus 0.18 with placebo, with weight falling 1.4 kg against a 0.7 kg gain on placebo. A later 16-week trial in 212 people using insulin glargine found that a composite endpoint of glycaemic and weight benefit was met by 25% on pramlintide versus 7% on placebo.
The honest reading is that the glycaemic effect is real but small, and that the weight effect, while consistent, is of the order of 1-2 kg. The most important practical finding is the hypoglycaemia signal: severe events clustered in the first four weeks and were largely attributable to failure to reduce mealtime insulin adequately, which is why the label mandates a substantial reduction at initiation. Uptake has consequently been limited, and pramlintide has remained a niche therapy. Interest in amylin pharmacology has since revived through long-acting analogues developed for obesity, which build on the same receptor biology with much longer duration of action.
Evidence assessment
High-quality evidence
Pramlintide holds FDA-approved labelling supported by several replicated 52-week randomised, double-blind, placebo-controlled trials in both type 1 and type 2 diabetes. The evidence for efficacy is genuinely strong in methodological terms, though the effect size is modest: HbA1c reductions were typically 0.3-0.7 percentage points, with weight differences of 1-2 kg. All four cited studies were individually verified, and one title was corrected.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Preclinical only
Mean HbA1c fell 0.67 percentage points with pramlintide, significantly more than placebo, with a favourable weight profile. Severe hypoglycaemia was more frequent than with placebo during the first month.
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial Preclinical only
HbA1c fell 0.62 percentage points at 120 micrograms twice daily versus 0.18 with placebo, and body weight fell 1.4 kg versus a 0.7 kg gain on placebo. Nausea was the main adverse effect.
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial Preclinical only
HbA1c reductions of approximately 0.3 percentage points were sustained at 52 weeks with a weight difference of about 1.8 kg favouring pramlintide, and three times as many patients reached target. Insulin dose did not need to be increased.
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin Preclinical only
A composite endpoint of HbA1c and weight benefit was met by 25% on pramlintide versus 7% on placebo (p<0.001), with greater reductions in HbA1c and postprandial glucose and weight loss rather than the gain seen on placebo.
Safety
The boxed warning for severe insulin-induced hypoglycaemia is the defining safety issue: events occur typically within three hours of dosing, are concentrated in the first weeks of treatment, and are prevented by substantial pre-emptive reduction of mealtime insulin. Nausea is very common, affecting roughly half of patients with type 1 diabetes in trials, and is dose-limiting; it usually abates over several weeks. Anorexia, vomiting, headache, fatigue and abdominal pain occur frequently. Pramlintide is contraindicated in confirmed gastroparesis and in hypoglycaemia unawareness, since both the mechanism and the risk profile depend on intact gastric handling and hypoglycaemia perception. It must never be mixed with insulin in the same syringe because the formulation pH differs. Delayed gastric emptying can slow absorption of oral medicines requiring rapid onset. Injection-site reactions are usually mild.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Not licensed. Pramlintide was never granted a marketing authorisation in the European Union or the United Kingdom; the European application did not proceed to approval and was withdrawn by the applicant. It is not available on prescription in the UK and there is no NHS route to supply. Any material sold as pramlintide in the UK is outside the regulated medicines supply chain. |
| United States | Approved by the FDA in March 2005 as an adjunct treatment in patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glucose control despite optimal insulin therapy. The label carries a boxed warning stating that pramlintide, when co-administered with insulin, can cause severe hypoglycaemia, usually within three hours of injection and particularly in type 1 diabetes, and that a substantial reduction in mealtime insulin dose is required at initiation. It must not be mixed in the same syringe as insulin. Prescription-only. |
| WADA (sport) | Not prohibited. Pramlintide and amylin receptor agonists do not appear on the WADA Prohibited List. Note that this is separate from insulin, which is prohibited at all times under section S4; an athlete using pramlintide will almost invariably be using insulin as well, and the insulin requires a Therapeutic Use Exemption. |
Questions
Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. Anyone who loses beta-cell function loses amylin as well as insulin, so insulin replacement alone leaves half the physiology unreplaced. Pramlintide was developed to address that gap.
The two formulations have incompatible pH values, and mixing alters the pharmacokinetics of both. Pramlintide is formulated at an acidic pH while most insulins are near neutral. Separate injections at separate sites are required.
No. Weight reduction in the pivotal trials was consistently only 1-2 kg relative to placebo. It is licensed as a mealtime glycaemic adjunct, not for obesity. Longer-acting amylin analogues developed since for weight management are separate compounds.
No. It has never held a UK or European marketing authorisation and is not available on prescription or through the NHS. Products offered as pramlintide in the UK sit outside the regulated medicines supply chain, with no assurance of identity, purity or sterility.